Literature DB >> 23864310

An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke.

David M Kent1, Robin Ruthazer, Christian Weimar, Jean-Louis Mas, Joaquín Serena, Shunichi Homma, Emanuele Di Angelantonio, Marco R Di Tullio, Jennifer S Lutz, Mitchell S V Elkind, John Griffith, Cheryl Jaigobin, Heinrich P Mattle, Patrik Michel, Marie-Louise Mono, Krassen Nedeltchev, Federica Papetti, David E Thaler.   

Abstract

OBJECTIVE: We aimed to create an index to stratify cryptogenic stroke (CS) patients with patent foramen ovale (PFO) by their likelihood that the stroke was related to their PFO.
METHODS: Using data from 12 component studies, we used generalized linear mixed models to predict the presence of PFO among patients with CS, and derive a simple index to stratify patients with CS. We estimated the stratum-specific PFO-attributable fraction and stratum-specific stroke/TIA recurrence rates.
RESULTS: Variables associated with a PFO in CS patients included younger age, the presence of a cortical stroke on neuroimaging, and the absence of these factors: diabetes, hypertension, smoking, and prior stroke or TIA. The 10-point Risk of Paradoxical Embolism score is calculated from these variables so that the youngest patients with superficial strokes and without vascular risk factors have the highest score. PFO prevalence increased from 23% (95% confidence interval [CI]: 19%-26%) in those with 0 to 3 points to 73% (95% CI: 66%-79%) in those with 9 or 10 points, corresponding to attributable fraction estimates of approximately 0% to 90%. Kaplan-Meier estimated stroke/TIA 2-year recurrence rates decreased from 20% (95% CI: 12%-28%) in the lowest Risk of Paradoxical Embolism score stratum to 2% (95% CI: 0%-4%) in the highest.
CONCLUSION: Clinical characteristics identify CS patients who vary markedly in PFO prevalence, reflecting clinically important variation in the probability that a discovered PFO is likely to be stroke-related vs incidental. Patients in strata more likely to have stroke-related PFOs have lower recurrence risk.

Entities:  

Mesh:

Year:  2013        PMID: 23864310      PMCID: PMC3775694          DOI: 10.1212/WNL.0b013e3182a08d59

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

Authors:  David M Kent; Rodney A Hayward
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

2.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.

Authors:  J L Mas; C Arquizan; C Lamy; M Zuber; L Cabanes; G Derumeaux; J Coste
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

3.  Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm.

Authors:  C Lamy; C Giannesini; M Zuber; C Arquizan; J F Meder; D Trystram; J Coste; J L Mas
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

4.  Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study.

Authors:  Joaquín Serena; Joan Marti-Fàbregas; Estevo Santamarina; Juan Jesús Rodríguez; María Jesús Perez-Ayuso; Jaime Masjuan; Tomás Segura; Jaime Gállego; Antonio Dávalos
Journal:  Stroke       Date:  2008-09-25       Impact factor: 7.914

5.  Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?

Authors:  Alawi A Alsheikh-Ali; David E Thaler; David M Kent
Journal:  Stroke       Date:  2009-05-14       Impact factor: 7.914

6.  Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt.

Authors:  C Weimar; D N Holle; J Benemann; E Schmid; U Schminke; R L Haberl; H-C Diener; M Goertler
Journal:  Cerebrovasc Dis       Date:  2009-07-24       Impact factor: 2.762

7.  Atherosclerotic burden findings in young cryptogenic stroke patients with and without a patent foramen ovale.

Authors:  Josep Rodés-Cabau; Martin Noël; Alier Marrero; Donald Rivest; Ariane Mackey; Christine Houde; Elizabeth Bédard; Eric Larose; Steve Verreault; Marc Peticlerc; Philippe Pibarot; Peter Bogaty; Olivier F Bertrand
Journal:  Stroke       Date:  2008-12-18       Impact factor: 7.914

8.  Cerebral emboli of paradoxical origin.

Authors:  H R Jones; L R Caplan; P C Come; N W Swinton; D J Breslin
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

9.  Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study.

Authors:  Marco R Di Tullio; Shunichi Homma; Zhezhen Jin; Ralph L Sacco
Journal:  J Am Coll Cardiol       Date:  2008-09-02       Impact factor: 24.094

10.  The risk of paradoxical embolism (RoPE) study: initial description of the completed database.

Authors:  David E Thaler; Emanuele Di Angelantonio; Marco R Di Tullio; Jennifer S Donovan; John Griffith; Shunichi Homma; Cheryl Jaigobin; Jean-Louis Mas; Heinrich P Mattle; Patrik Michel; Marie-Luise Mono; Krassen Nedeltchev; Federica Papetti; Robin Ruthazer; Joaquín Serena; Christian Weimar; Mitchell S V Elkind; David M Kent
Journal:  Int J Stroke       Date:  2012-08-09       Impact factor: 5.266

View more
  100 in total

1.  Controversies in cardioembolic stroke.

Authors:  Benjamin S Wessler; David M Kent
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-01

Review 2.  Prevention of recurrent stroke in patients with patent foramen ovale.

Authors:  Benjamin S Wessler; David M Kent
Journal:  Neurol Clin       Date:  2015-02-28       Impact factor: 3.806

Review 3.  Cardioembolic Stroke.

Authors:  Hooman Kamel; Jeff S Healey
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

Review 4.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

Authors:  David M Kent; Ewout Steyerberg; David van Klaveren
Journal:  BMJ       Date:  2018-12-10

Review 5.  Current management aspects in adult congenital heart disease: non-surgical closure of patent foramen ovale.

Authors:  Kaivan Vaidya; Chinmay Khandkar; David Celermajer
Journal:  Cardiovasc Diagn Ther       Date:  2018-12

Review 6.  Echocardiographic features of PFOs and paradoxical embolism: a complicated puzzle.

Authors:  Constantina Aggeli; Athanasios Verveniotis; Efstathia Andrikopoulou; Emmanouil Vavuranakis; Konstadinos Toutouzas; Dimitrios Tousoulis
Journal:  Int J Cardiovasc Imaging       Date:  2018-06-28       Impact factor: 2.357

7.  Caught in the Act: Paradoxical Emboli.

Authors:  Michael E Layoun; Eric H Yang; Henry M Honda; Jonathan M Tobis
Journal:  Tex Heart Inst J       Date:  2018-04-07

8.  Secondary prevention of cryptogenic stroke in patients with patent foramen ovale: a systematic review and meta-analysis.

Authors:  Elisa Maria Fiorelli; Tiziana Carandini; Delia Gagliardi; Viviana Bozzano; Mattia Bonzi; Eleonora Tobaldini; Giacomo Pietro Comi; Elio Angelo Scarpini; Nicola Montano; Monica Solbiati
Journal:  Intern Emerg Med       Date:  2018-07-21       Impact factor: 3.397

9.  Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.

Authors:  Scott E Kasner; Balakumar Swaminathan; Pablo Lavados; Mukul Sharma; Keith Muir; Roland Veltkamp; Sebastian F Ameriso; Matthias Endres; Helmi Lutsep; Steven R Messé; J David Spence; Krassen Nedeltechev; Kanjana Perera; Gustavo Santo; Veronica Olavarria; Arne Lindgren; Shrikant Bangdiwala; Ashkan Shoamanesh; Scott D Berkowitz; Hardi Mundl; Stuart J Connolly; Robert G Hart
Journal:  Lancet Neurol       Date:  2018-09-28       Impact factor: 44.182

10.  Endocardial Device Leads in Patients with Patent Foramen Ovale: Echocardiographic Correlates of Stroke/TIA and Mortality.

Authors:  Shiva P Ponamgi; Vaibhav R Vaidya; Christopher V Desimone; Amit Noheria; David O Hodge; Joshua P Slusser; Naser M Ammash; Charles J Bruce; Alejandro A Rabinstein; Paul A Friedman; Samuel J Asirvatham
Journal:  Pacing Clin Electrophysiol       Date:  2017-02-07       Impact factor: 1.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.